Newsroom

August 4, 2022
Second quarter 2022 net sales of $1.22 billion , an increase of 2% year-over-year; GAAP net loss attributable to Covetrus of $(4) million Non-GAAP organic net sales growth of 5% year-over-year Non-GAAP adjusted EBITDA was flat year-over-year at $66 million , including a $2 million year-over-year
July 28, 2022
PORTLAND, Maine --(BUSINESS WIRE)--Jul. 28, 2022-- Covetrus® (NASDAQ: CVET), a global leader in animal-health technology and services, announced today that it will release second quarter 2022 results before the markets open on Thursday, August 4, 2022 .
May 20, 2022
Today, affiliates of CD&R and TPG Global, LLC (together, the “Sponsors”) made a proposal to acquire all of the outstanding shares of Covetrus’ common stock that are not owned by the Sponsors or their affiliates for cash consideration of $21.00 per share.
May 5, 2022
First quarter 2022 net sales of $1.15 billion , an increase of 4% year-over-year; GAAP net loss attributable to Covetrus of $(2) million Non-GAAP organic net sales growth of 6% year-over-year Non-GAAP adjusted EBITDA increased 11% year-over-year to $63 million Full-year 2022 non-GAAP organic net
March 16, 2022
Former Chief Economist at the AVMA to Lead Covetrus Subsidiary PORTLAND, Maine --(BUSINESS WIRE)--Mar. 16, 2022-- Veterinary Study Groups, Inc. (VSG), a subsidiary of Covetrus ® (NASDAQ: CVET), a global leader in animal-health technology and services, has named Matt Salois , Ph.D.
February 24, 2022
Fourth quarter 2021 net sales of $1.12 billion , unchanged year-over-year; GAAP net loss attributable to Covetrus of $(3) million Non-GAAP organic net sales growth of 2% year-over-year Non-GAAP adjusted EBITDA increased 13% year-over-year to $63 million Full-year 2021 net sales of $4.58 billion ,